Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business
The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.